Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial-Reference-Cited by-同舟云学术

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

Published:2016-04 Issue:10027 Volume:387 Page:1551-1560
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Lonial Sagar,Weiss Brendan M,Usmani Saad Z,Singhal Seema,Chari Ajai,Bahlis Nizar J,Belch Andrew,Krishnan Amrita,Vescio Robert A,Mateos Maria Victoria,Mazumder Amitabha,Orlowski Robert Z,Sutherland Heather J,Bladé Joan,Scott Emma C,Oriol Albert,Berdeja Jesus,Gharibo Mecide,Stevens Don A,LeBlanc Richard,Sebag Michael,Callander Natalie,Jakubowiak Andrzej,White Darrell,de la Rubia Javier,Richardson Paul G,Lisby Steen,Feng Huaibao,Uhlar Clarissa M,Khan Imran,Ahmadi Tahamtan,Voorhees Peter M

Publisher

Elsevier BV

Subject

General Medicine

Reference24 articles.

1. Multiple myeloma;Rollig;Lancet,2015

2. Improved survival in multiple myeloma and the impact of novel therapies;Kumar;Blood,2008

3. Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study;Turesson;J Clin Oncol,2010

4. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study;Kumar;Leukemia,2012

5. Elotuzumab and daratumumab: emerging new monoclonal antibodies for multiple myeloma;Kuroda;Expert Rev Anticancer Ther,2013

Cited by 740 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Promising Therapeutic Strategies for Hematologic Malignancies: Innovations and Potential;Molecules;2024-09-09

2. Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Study;Annals of Hematology;2024-09-04

3. CD38 regulates chronic lymphocytic leukemia proliferation via CD45 phosphatase activity;Molecular Therapy: Oncology;2024-09

4. The Role of Monoclonal Antibodies in the Treatment of Myeloma Kidney Disease;Pharmaceuticals;2024-08-05

5. Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial;The Lancet Oncology;2024-08